Well-Funded Denali Adds CMO Carole Ho, Another Genentech Alum

Denali Therapeutics has named Carole Ho as its chief medical officer and head of development. Ho becomes the latest ex-Genentech executive to join the neuroscience startup, which launched in May with $217 million in backing.

Ho, who was previously vice president of early clinical development at Genentech, joins at least three other alums at Denali, which aims to develop therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Denali CEO Ryan Watts was Genentech’s director of neuroscience; COO Alex Schuth was Genentech’s top neuroscience dealmaker; and chairman Marc  Tessier-Lavigne was Genentech’s chief scientific officer before taking over as president of Rockefeller University in New York in 2011.

Author: Alex Lash

I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy. View all posts by Alex Lash